ClinicalTrials.gov (n.d.-d) Assessment of single doses of oral dexanabinol in healthy subjects.
https://ClinicalTrials.gov/show/NCT02054754
ClinicalTrials.gov (n.d.-e) Efficacy and safety of dronabinol in the improvement of chemotherapy-
induced and tumor-related symptoms in advanced pancreatic cancer. https://ClinicalTrials.gov/
show/NCT03984214
ClinicalTrials.gov (n.d.-f) Phase 1 study to evaluate safety and usefulness of an ayurvedic cannabis
preparation in the peri-operative period in breast and oral cavity squamous cell cancer. https://
ClinicalTrials.gov/show/CTRI/2020/06/026049
ClinicalTrials.gov (n.d.-g) Study on cannabinoid receptor expression in gastrointestinal diseases.
https://ClinicalTrials.gov/show/NCT02735941
ClinicalTrials.gov (n.d.-h) TN-TC11G (THC+CBD) combination with temozolomide and radio-
therapy in patients with newly-diagnosed glioblastoma. https://ClinicalTrials.gov/show/NCT03
529448
Colodenco D, Palomares O, Celis C, KaplanA DC (2018) Moving toward consensus on diagnosis
and management of severe asthma in adults. Curr Med Res Opin 34(3):387–399
Consroe P, Wolkin A (1977a) Cannabidiol-antiepileptic drug comparisons and interactions in
experimentally induced seizures in rats. J Pharmacol Exp Ther 201:26–32
Consroe PF, Wolkin AL (1977b) Anticonvulsant interaction of cannabidiol and ethosuximide in
rats. J Pharm Pharmacol 29:500–501
Consroe P, Musty R, Rein J et al (1997) The perceived effects of smoked cannabis on patients with
multiple sclerosis. Eur Neurol 38(1):44–48
Cortesi M, Fusar-Poli P (2007) Potential therapeutical effects of cannabidiol in children with
pharmacoresistant epilepsy. Med Hypotheses 68:920–921
Curtis A, Rickards H (2006) Nabilone could treat chorea and irritability in Huntington's disease. J
Neuropsychiatry Clin Neurosci 18:553–554
Dando I, Donadelli M, Costanzo C, Pozza DE, D’Alessandro A, Zolla L et al (2013) Cannabinoids
inhibit energetic metabolism and induce AMPK-dependent autophagy in pancreatic cancer
cells. Cell Death Dis 4:e664
Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC (1988) Determination and
characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34:605–613
Esposito G, De Filippis D, Maiuri MC (2006) Cannabidiol inhibits inducible nitric oxide synthase
protein expression and nitric oxide production in β-amyloid stimulated PC12 neurons through
p38 MAP kinase and NF-kappaB involvement. Neurosci Lett 399:91–95
Esposito G, Scuderi C, Savani C (2007) Cannabidiol in vivo blunts β-amyloid induced
neuroinflammation by suppressing IL-1β and iNOS expression. Br J Pharmacol 151:1272–1279
Fogli S, Nieri P, Chicca A, AdinolfiB, Mariotti V, Iacopetti P et al (2006) Cannabinoid derivatives
induce cell death in pancreatic MIA PaCa-2 cells via a receptor-independent mechanism. FEBS
Lett 580:1733–1739
Garcia-Gil L, de Miguel R, Romero J et al (1999) Perinatal delta9-tetrahydrocannabinol exposure
augmented the magnitude of motor inhibition caused by GABA (B), but not GABA (A),
receptor agonists in adult rats. Neurotoxicol Teratol 21(3):277–283
Global Initiative for Asthma (2020) Global strategy for asthma management and prevention
Gordon E, Devinsky O (2001) Alcohol and marijuana: effects on epilepsy and use by patients with
epilepsy. Epilepsia 42:1266–1272
Han KH, Lim S, Ryu J (2009) CB1 and CB2 cannabinoid receptors differentially regulate the
production of reactive oxygen species by macrophages. Cardiovasc Res 84:378–386
Haustein M, Ramer R, Linnebacher M, Manda K, Hinz B (2014) Cannabinoids increase lung cancer
cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1. Biochem Pharmacol
92:312–325
Holland ML, Panetta JA, Hoskins JM, Bebawy M, Roufogalis BD, Allen JD, Arnold JC (2006) The
effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells.
Biochem Pharmacol 71(8):1146–1154
Holland ML, Lau DTT, Allen JD, Arnold JC (2007) The multidrug transporter ABCG2 (BCRP) is
inhibited by plant-derived cannabinoids. Br J Pharmacol 152(5):815–824
198
S. Singh et al.